StarBright Blue and StarBright Yellow Dyes Conjugated to Highly Validated Antibodies for Conventional and Full Spectrum Flow Cytometry in Immunology Research

HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of both the StarBright™ Blue-series and StarBright™ Yellow-series Dyes to provide greater flexibility in conventional and full spectrum flow cytometry applications. Offering exceptional brightness with narrow excitation and emission profiles for precise resolution, the dyes expand research capabilities across the blue (488 nm) and yellow (561 nm) lasers

Each dye in the Bio-Rad range of highly stable StarBright Dyes is conjugated to flow validated antibodies, supporting flow cytometry panel design in immunology research. StarBright Blue Dyes 580, 615, 675, 700, 765, and 810 are excitable by the 488 nm laser, and StarBright Yellow Dyes 575, 605, 665, 720, and 800 by the 561 nm laser, with low background. Compared to PE and PE tandems, StarBright Blue Dyes are true 488 nm excitable dyes and StarBright Yellow Dyes offer reduced excitation by the 488 nm laser. They can be used in combination with other StarBright Dyes and traditional fluorophores.

StarBright Dyes are compatible with most experimental protocols and flow cytometers, including the Bio-Rad ZE5 Cell Analyzer, without the need for special buffers. Minimal lot-to-lot variation helps to ensure reproducible and consistent staining, and the dyes are resistant to photobleaching with no loss of signal in fixation.

“The continued development of the Bio-Rad StarBright Dye portfolio, now totaling 28 dyes and spanning multiple lasers, gives researchers greater choice and flexibility across multiplex flow cytometry applications, offering superior alternatives to existing dyes,” said Mike Blundell, PhD, Product Manager, Flow Cytometry, Life Science Group, Bio-Rad. “With the launch of the StarBright Blue and StarBright Yellow Dyes, Bio-Rad now has the most comprehensive series of new dyes specifically designed for flow cytometry.”

To learn more about Bio-Rad StarBright Dyes, visit bio-rad-antibodies.com/flow-cytometry-starbright-dyes.

BIO-RAD and STARBRIGHT are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner. 

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With 70 years of focus on quality and customer service, our products advance the scientific discovery process and improve healthcare. Our customers are universities, research institutions, hospitals, biotechnology and pharmaceutical companies, as well as public health and commercial laboratories including food safety and environmental quality testing facilities. Based in Hercules, California, Bio-Rad has a global network of operations with approximately 8,200 employees worldwide and $2.9 billion in revenues in 2021. For more information, please visit bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, supply chain risks, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Media Contacts:

Bio-Rad Laboratories, Inc.

Katrina Academia, Inbound Marketing Manager

[email protected]

Zyme Communications
Esmé Walters

[email protected]